Skip to content

Merck To Acquire Eyebiotech

๐Œ๐ž๐ซ๐œ๐ค ๐ญ๐จ ๐š๐œ๐ช๐ฎ๐ข๐ซ๐ž ๐„๐ฒ๐ž๐›๐ข๐จ๐ญ๐ž๐œ๐ก ๐ข๐ง ๐ ๐ซ๐จ๐ฎ๐ง๐๐›๐ซ๐ž๐š๐ค๐ข๐ง๐  $3 ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ƒ๐ž๐š๐ฅ: ๐€ ๐Œ๐š๐ฃ๐จ๐ซ ๐‹๐ž๐š๐ฉ ๐ข๐ง๐ญ๐จ ๐Ž๐ฉ๐ก๐ญ๐ก๐š๐ฅ๐ฆ๐ข๐œ๐ฌ

๐Ÿ’ฒMerck is set to acquire Eyebiotech Limited (EyeBio) in a deal worth up to $3 billion, marking a significant expansion into the ophthalmic industry. The agreement includes an upfront payment of $1.3 billion in cash and up to $1.7 billion in development, regulatory, and commercial milestone payments.

๐ŸคEyeBio, co-founded by Dr. David R. Guyer, focuses on developing treatments for retinal disease. With Merckโ€™s resources and infrastructure, EyeBio will be well-positioned to advance its investigational pipeline. This acquisition strengthens Merckโ€™s portfolio and underscores its commitment to addressing unmet medical needs in ophthalmology.